Abstract
Low-dose oral steroid use at the onset of interferon beta-1b (IFNbeta-1b) therapy in relapsing-remitting multiple sclerosis (RR-MS) patients reduces flulike symptoms. To determine the mechanism by which steroid treatment minimizes these side effects, we analyzed the percentage of interleukin-6 (IL-6)-, interferon-gamma (IFN-gamma)-, tumor necrosis factor alpha (TNF-alpha)-, and IL-10-producing cells before and after 3 months of IFNbeta-1b therapy onset. Our results support a relationship between IL-6 induction and fever. Such side effects can be ameliorated by steroids.
Publication types
-
Clinical Trial
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Acetaminophen / administration & dosage*
-
Acetaminophen / therapeutic use
-
Administration, Oral
-
Adult
-
Analgesics, Non-Narcotic / administration & dosage
-
Analgesics, Non-Narcotic / therapeutic use
-
Dose-Response Relationship, Drug
-
Drug Therapy, Combination
-
Fever / metabolism
-
Glucocorticoids / administration & dosage*
-
Glucocorticoids / therapeutic use
-
Humans
-
Influenza, Human / drug therapy*
-
Influenza, Human / etiology*
-
Influenza, Human / metabolism
-
Interferon beta-1a
-
Interferon beta-1b
-
Interferon-beta / adverse effects*
-
Interferon-beta / therapeutic use
-
Interleukin-6 / antagonists & inhibitors
-
Interleukin-6 / biosynthesis*
-
Middle Aged
-
Multiple Sclerosis / therapy*
-
Prednisone / administration & dosage*
-
Prednisone / therapeutic use
Substances
-
Analgesics, Non-Narcotic
-
Glucocorticoids
-
Interleukin-6
-
Interferon beta-1b
-
Acetaminophen
-
Interferon-beta
-
Prednisone
-
Interferon beta-1a